Camlin Fine Sciences Q1FY27 Results: Net Loss Widens to ₹317 Crore
Camlin Fine Sciences reported Q1FY27 results with standalone net loss of ₹317.06 million and consolidated net loss of ₹99.61 million. Total income from operations was ₹2,224.86 million (standalone) and ₹5,198.79 million (consolidated). EPS stood at ₹(0.64) standalone and ₹(0.53) consolidated.
The increase in net loss is a material financial event that could impact investor sentiment and the company's stock performance.
The company reported a significant widening of net losses on both standalone and consolidated bases for the quarter ended June 30, 2026.
Camlin Fine Sciences Limited announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a total income from operations of ₹2,224.86 million on a standalone basis and ₹5,198.79 million on a consolidated basis.
On a standalone basis, the company posted a net profit/loss after tax and non-controlling interests of ₹(317.06) million. This marks a significant increase in losses compared to the previous periods. The total comprehensive income for the period stood at ₹(86.28) million.
Consolidated figures also showed a net profit/loss after tax and non-controlling interests of ₹(99.61) million for the quarter. The total comprehensive income for the consolidated entity was ₹(66.42) million.
Earnings per share (EPS) on a standalone basis were ₹(0.64) for basic and diluted EPS. On a consolidated basis, the basic and diluted EPS were ₹(0.53).
The company's registered office is located in Mumbai, Maharashtra. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 11, 2026. The detailed financial results are available on the company's website and stock exchange websites.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.